With seasonal influenza activity rising earlier than typical patterns suggest, health officials are urging the public to seek immunization, highlighting a new technological option available for older adults. For the first time, a flu vaccine utilizing messenger RNA (mRNA) technology is available to Americans aged 50 and older, offering a significant shift from the decades-old methods used to produce traditional shots.
According to data from the Centers for Disease Control and Prevention (CDC), the current flu season is gaining momentum ahead of schedule. While traditional vaccines remain a staple of public health efforts, the introduction of mRNA technology—the same platform used for high-profile COVID-19 immunizations—is designed to address long-standing limitations in vaccine production and efficacy.
Dr. Ann Falsey, an infectious disease specialist at the University of Rochester School of Medicine, explains that the fundamental difference lies in how the body is taught to recognize the virus. Traditional vaccines typically involve injecting a piece of the virus protein, often grown in chicken eggs or cell cultures, to trigger an immune response. In contrast, mRNA vaccines provide the body with a genetic blueprint.
“This is an RNA vaccine, and what that does is you give the message to your body so that your body can then make the protein and have an immune reaction to the protein,” Dr. Falsey noted. This approach bypasses the lengthy manufacturing process required for egg-based vaccines, which can take six to nine months of preparation as scientists attempt to predict which strains will circulate nearly a year in advance.
The speed of mRNA production allows for much later adjustments to the vaccine formula if a new or unexpected strain emerges. Beyond the logistical advantages, early data suggests the new technology may offer superior protection. Initial studies indicate that the mRNA flu shot is approximately 27% more effective than standard-dose traditional vaccines.
Currently, the FDA has approved the mRNA flu vaccine specifically for those aged 50 and older. Dr. Falsey explains that this age restriction is primarily a result of the demographics included in the initial clinical studies. Older adults are prioritized because they face a significantly higher risk of serious illness or hospitalization from influenza. While the vaccine would likely work in younger populations, it does carry slightly higher “reactogenicity,” meaning patients might experience a more frequent sore arm or mild fatigue the day after the injection.
For adults in the 50-to-64 age bracket, the new mRNA option fills a specific gap in preventative care. While those 65 and older have long had access to “high-dose” or adjuvanted vaccines—which use extra protein or additives to boost the immune response—these products are generally not approved for the younger 50-plus demographic. The mRNA shot provides this group with a higher-potency alternative that was previously unavailable.
Addressing common concerns regarding the speed of mRNA development, Dr. Falsey emphasized that the technology was not invented during the recent pandemic. Researchers had been working on mRNA platforms for nearly two decades before they reached wide-scale deployment. She further addressed myths regarding genetic alteration, stating with “100% certainty” that the vaccine cannot integrate into a recipient’s DNA.
While mRNA represents the future of vaccine manufacturing, Dr. Falsey does not believe traditional protein-based shots will disappear anytime soon. Public health strategies will likely continue to offer multiple options, including cell-based and egg-based vaccines, to ensure broad coverage and provide alternatives for those who may be hesitant about newer technologies.
